ETG Prevents Chemotherapy Hair Loss

Article by HairlossTalk.com

Current Technology Corporation (OTC Bulletin Board: CRTCF) today announced that Dr. Tim Meakin has presented preliminary results in Auckland, New Zealand, from a single center pilot clinical trial to assess the efficacy of the ETG (Electrotrichogenesis) device in the prevention or reduction of hair loss in patients with breast cancer undergoing chemotherapy...Dr. Meakin reported that thirteen women completed the study. Twelve of the thirteen had the same amount of hair or an increase in the amount of hair at the conclusion of their chemotherapy regimen when compared to baseline. All of the women were diagnosed with breast cancer, treated with CMF chemotherapy over approximately 24 weeks, and received concurrent ETG treatments.

CMF is a combination of the chemotherapy agents Cyclophosphamide, Methotrexate and Fluorouracil (5FU). This combination is a chemotherapy regime frequently prescribed in New Zealand, the United States and many other countries. Alopecia (hair loss) as a result of cancer chemotherapy is a major source of negative changes to self-concept and body image and one of the side effects to chemotherapy people fear most.

Therefore, in addition to assessing hair quantity, quality of life was assessed in this clinical study. All of the women reported that ETG treatments to prevent or reduce chemotherapy induced hair loss, assisted them maintain their sense of well being, and self-esteem.

A full report on the pilot clinical study has been submitted to the medical literature for publication.

Current Technology Corporation is the developer of ETG (Electrotrichogenesis), a patented electrotherapeutic device that provides a clinically proven medical treatment for hair loss, in suitable candidates both male and female. ETG treatments are presently available in several countries around the world.

HLT

© HairlossTalk.com - All Rights Reserved.
The content found here is not intended as a substitute for professional medical advice.
For permission to duplicate any content, please Contact Us.
Make sure you're Subscribed to the Newsletter! We never share your info.